As the focus of cancer treatment has shifted—from directly targeting and destroying a tumor to leveraging the body's immune system to fight the tumor—there has been a corresponding change in how researchers use animal models in their preclinical oncology studies. While xenograft studies utilizing immunodeficient models once served as the primary approach for oncology research, the rise in immunotherapy has moved syngeneic tumor models back into the... Read More